OHR Pharmaceutical Inc.

Financials

v3.8.0.1
Consolidated Balance Sheets (Unaudited) - USD ($)
Dec. 31, 2017
Sep. 30, 2017
CURRENT ASSETS    
Cash and Cash Equivalents $ 8,724,057 $ 12,801,085
Prepaid expenses and other current assets 100,722 223,278
Total Current Assets 8,824,779 13,024,363
EQUIPMENT, net 60,890 63,757
OTHER ASSETS    
Security deposit 12,243
Intangible assets, net 13,805,484 14,087,602
Goodwill 740,912 740,912
TOTAL ASSETS 23,432,065 27,928,877
CURRENT LIABILITIES    
Accounts payable and accrued expenses 3,598,471 4,827,525
Notes payable 106,387
Total Current Liabilities 3,598,471 4,933,912
Long-term liability 150,000 150,000
TOTAL LIABILITIES 3,748,471 5,083,912
STOCKHOLDERS' EQUITY    
Preferred stock, Series B; 6,000,000 shares authorized, $0.0001 par value, 0 shares issued and outstanding, respectively  
Common stock; 180,000,000 shares authorized, $0.0001 par value, 56,421,428 and 56,196,428 shares issued and outstanding, respectively 5,642 5,619
Additional paid-in capital 131,917,917 130,927,953
Accumulated deficit (112,239,965) (108,088,607)
Total Stockholders' Equity 19,683,594 22,844,965
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 23,432,065 $ 27,928,877
v3.8.0.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Dec. 31, 2017
Dec. 31, 2016
OPERATING EXPENSES    
General and administrative $ 1,510,032 $ 1,746,356
Research and development 2,387,731 4,931,144
Depreciation and amortization 284,986 298,435
TOTAL OPERATING LOSS 4,182,749 6,975,935
OTHER INCOME (EXPENSE)    
Other income (expense) 31,391 281
Total Other Income (Expense) 31,391 281
LOSS FROM OPERATIONS BEFORE INCOME TAXES (4,151,358) (6,975,654)
NET LOSS $ (4,151,358) $ (6,975,654)
BASIC AND DILUTED LOSS PER SHARE (in dollars per share) $ (.07) $ (.21)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING:    
BASIC AND DILUTED (in shares) 56,203,765 32,836,505
v3.8.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Dec. 31, 2017
Dec. 31, 2016
OPERATING ACTIVITIES    
Net loss $ (4,151,358) $ (6,975,654)
Adjustments to reconcile net loss to net cash used by operating activities:    
Common stock issued for services 135,701 440,052
Stock option expense 629,286 566,573
Depreciation 2,867 15,736
Amortization of intangible assets 282,118 282,699
Changes in operating assets and liabilities    
Prepaid expenses and deposits 122,556 247,926
Accounts payable and accrued expenses (1,229,054) (507,793)
Security Deposit used 12,243  
Net Cash Used in Operating Activities (4,195,641) (5,930,461)
INVESTING ACTIVITIES    
Purchase of property and equipment (4,833)
Net Cash Provided by (Used in) Investing Activities (4,833)
FINANCING ACTIVITIES    
Proceeds from issuance of common stock for cash   6,846,483
Proceeds from warrants exercised for cash 225,000 118,801
Repayments of short-term notes payable (106,387) (87,798)
Net Cash Provided by (Used in) Financing Activities 118,613 6,877,486
NET CHANGE IN CASH (4,077,028) 942,192
CASH AT BEGINNING OF PERIOD 12,801,085 12,546,890
CASH AT END OF PERIOD 8,724,057 13,489,082
CASH PAID FOR:    
Interest $ 1,770 $ 1,320